RPL15A Antibody

What is RPL15 and what cellular functions does it perform in normal physiology?

RPL15 (ribosomal protein L15) is a 60S ribosomal protein with a calculated molecular weight of 24 kDa, though it is typically observed at approximately 27 kDa in experimental conditions . It plays a critical role in ribosome biogenesis, specifically in the formation of pre-60S ribosomal subunits. The protein consists of 204 amino acids and is encoded by the RPL15 gene (Gene ID: 6138) .

Functionally, RPL15 primarily localizes to the nucleolus, where it participates in ribosomal RNA synthesis and nascent ribosome assembly . Immunofluorescence studies have confirmed its co-localization with nucleolar markers such as nucleolin and fibrillarin, indicating its crucial role in ribosomal biogenesis pathways . The protein is essential for the stability of the 60S ribosomal subunit and interacts with other ribosomal proteins, notably RPL4, in maintaining ribosomal integrity .

What experimental applications are validated for RPL15 antibody use?

The RPL15 antibody (such as 16740-1-AP) has been validated for multiple experimental applications with specific optimal protocols for each technique:

The antibody has demonstrated positive Western blot detection in multiple cell lines including COLO 320, HeLa, K-562, and SGC-7901 cells, as well as in mouse brain tissue . For optimal results in each application, it is recommended to titrate the antibody concentration based on specific experimental conditions and sample types .

What tissue and species reactivity has been confirmed for RPL15 antibody?

The RPL15 antibody has been experimentally validated for reactivity across multiple species:

In terms of tissue specificity, positive immunohistochemical detection has been confirmed in human colon tissue . Cellular detection has been demonstrated in various cell lines including HeLa cells (human cervical cancer), COLO 320 (human colorectal cancer), K-562 (human myelogenous leukemia), and SGC-7901 (human gastric cancer) . The antibody's cross-reactivity across these species makes it valuable for comparative studies in different model systems.

What are the optimal protocols for antigen retrieval when using RPL15 antibody in immunohistochemistry?

For optimal antigen retrieval when using RPL15 antibody in IHC applications, the following protocol is recommended:

Primary method: Antigen retrieval with TE buffer at pH 9.0 has shown optimal results for RPL15 detection in tissue sections, particularly for human colon tissue samples .

Alternative method: If the primary method yields suboptimal results, citrate buffer at pH 6.0 can be used as an alternative .

The effectiveness of antigen retrieval is critical for RPL15 antibody binding, particularly in formalin-fixed, paraffin-embedded tissues where protein cross-linking may mask epitopes. Researchers should evaluate both methods to determine which provides optimal signal-to-noise ratio for their specific tissue samples.

What are the recommended storage and handling conditions to maintain RPL15 antibody integrity?

To maintain RPL15 antibody efficacy and stability, the following storage and handling conditions are recommended:

Storage temperature: Store at -20°C, where the antibody remains stable for one year after shipment .

Buffer composition: The antibody is supplied in PBS containing 0.02% sodium azide and 50% glycerol at pH 7.3 .

Aliquoting recommendations: For the -20°C storage temperature, aliquoting is unnecessary, which simplifies laboratory handling procedures .

Special considerations: The 20μl sized preparations contain 0.1% BSA, which helps maintain antibody stability .

Proper storage according to these specifications ensures optimal antibody performance across applications and prevents degradation or loss of binding specificity.

What controls should be included when designing RPL15 knockdown experiments?

When designing RPL15 knockdown experiments, the following controls and methodological considerations are essential:

Essential controls:

• Non-silencing/nonsense siRNA (NS siRNA) as negative control to account for non-specific effects of the transfection process

• Validation of knockdown efficiency through Western blot analysis using anti-RPL15 antibody and appropriate loading controls such as α-Tubulin

• Monitoring of cell viability and proliferation, as RPL15 knockdown has been shown to slightly decrease cell proliferation in experimental models

Methodological considerations:

• For B16-F10 melanoma models, shRNA-mediated knockdown has been successfully utilized to study RPL15 function in vivo

• In HeLa cells, specific RPL15 siRNAs (siRPL15-1 or -2) have effectively reduced endogenous protein levels

• Quantitative assessment of nucleolar morphology using nucleolin staining can be employed as a functional readout of successful RPL15 depletion

These controls ensure that the observed phenotypes are specifically attributable to RPL15 knockdown rather than experimental artifacts.

How does RPL15 inhibition modulate the tumor microenvironment in cancer models?

RPL15 inhibition significantly modulates the tumor microenvironment through multiple immunological mechanisms:

Effects on immune cell populations:

• Increases CTL (CD8+ granzyme B+ IFN-γ+) T cell population in the tumor microenvironment

• Decreases regulatory T cell (Foxp3+ CD4+) population in tumors

• Does not significantly affect the myeloid-derived suppressor cell population

Impact on DAMP secretion:
RPL15 knockdown induces damage-associated molecular pattern (DAMP) secretion from cancer cells, which activates STING-mediated antitumor immune responses . This secretion creates a more immunogenic tumor microenvironment.

Enhancement of immunotherapy response:
In the B16-F10 murine melanoma model, RPL15 knockdown has been shown to sensitize tumors to anti-PD-1 treatment. The increased CTL/Treg ratio in the tumor microenvironment following RPL15 knockdown contributes to this enhanced response to immune checkpoint blockade .

These findings suggest that targeting RPL15 could improve immunotherapy outcomes, particularly in tumors that are otherwise resistant to PD-1 blockade.

What is the relationship between RPL15 expression and cancer progression?

RPL15 has demonstrated significant associations with cancer development and progression across multiple cancer types:

In colon cancer:

• 56.5% (13 of 25) of colon cancer tissues showed elevated RPL15 levels compared to adjacent non-cancerous tissues

• This suggests RPL15 may serve as a potential biomarker or therapeutic target in colorectal cancer

In other cancer types:

• Elevated expression of RPL15 has been reported to promote lung metastasis in breast cancer cells

• RPL15 overexpression enhances proliferation of gastric cancer cells

Mechanistic implications:
The ribosomal stress induced by RPL15 inhibition triggers DAMP secretion, which contributes to antitumor immunity . This suggests that aberrant expression of ribosomal proteins like RPL15 may help cancer cells evade immune surveillance.

These findings collectively indicate that RPL15 plays a multi-faceted role in cancer biology, affecting both cancer cell-intrinsic properties and interactions with the tumor microenvironment.

How does RPL15 knockdown affect nucleolar morphology and function?

RPL15 knockdown induces distinctive changes in nucleolar morphology and function, demonstrating its essential role in nucleolar integrity:

Morphological alterations:

• Cells depleted of RPL15 exhibit an increased nucleolar area within the nucleus compared to control cells

• Quantitative image analysis reveals a significant expansion of nucleoli relative to nuclear area following RPL15 depletion

Functional consequences:

• The fluorescent density (IOD/Area) of nucleolin, a major nucleolar protein, notably decreases after RPL15 knockdown

• RPL15 is required for regulating pre-60S ribosomal subunit biogenesis

Methodological assessment:
Researchers have developed specific image-processing algorithms to quantitatively characterize these nucleolar morphology defects. This involves measuring the area of observed nucleoli and nucleus of each cell based on nucleolin and nuclear staining (DAPI signal), then calculating the ratio of nucleolar area relative to nuclear area .

These findings highlight the critical role of RPL15 in maintaining nucleolar structure and function, with implications for understanding ribosomal biogenesis in both normal and pathological conditions.

How does topotecan (TPT) interact with RPL15 and what are the therapeutic implications?

Topotecan (TPT), traditionally known as a topoisomerase I inhibitor, has been newly identified to interact with RPL15:

Mechanism of interaction:

• TPT binds directly to RPL15, inhibiting preribosomal subunit formation

• This interaction is independent of TPT's known target, topoisomerase I (TOP1)

• TPT specifically inhibits RPL15-RPL4 interactions and decreases RPL4 stability

Immunological consequences:

• TPT-induced inhibition of RPL15 triggers DAMP secretion from cancer cells

• This activates STING-mediated antitumor immune responses

• The effect creates immunogenic tumor microenvironments favorable for immunotherapy

Therapeutic potential:

• TPT's dual mechanism (TOP1 and RPL15 inhibition) suggests potential synergistic anticancer effects

• The finding opens possibilities for developing RPL15-specific inhibitors that might be less cytotoxic than TPT but retain immunostimulatory effects

• Combination therapy of TPT with immune checkpoint inhibitors like anti-PD-1 antibodies shows promise based on the immunomodulatory effects of RPL15 inhibition

This discovery of RPL15 as a novel TPT target expands our understanding of how camptothecin derivatives might enhance cancer immunotherapy beyond their conventional cytotoxic mechanisms.

What experimental methods can be used to assess RPL15-mediated ribosomal stress responses?

Researchers can employ several experimental approaches to assess RPL15-mediated ribosomal stress responses:

Nucleolar morphology analysis:

• Immunofluorescence analysis using antibodies against nucleolar markers (nucleolin, fibrillarin, or UBF) after RPL15 depletion

• Quantitative image analysis measuring nucleolar area relative to nuclear area

• Calculation of fluorescent density (IOD/Area) of nucleolar proteins

DAMP secretion assessment:

• Measurement of damage-associated molecular patterns (DAMPs) released from cells following RPL15 knockdown or inhibition

• Evaluation of STING pathway activation markers downstream of DAMP signaling

Immune response characterization:

• Flow cytometric analysis of tumor-infiltrating lymphocytes, particularly CD8+ granzyme B+ IFN-γ+ T cells and Foxp3+ CD4+ T cells

• Assessment of tumor sensitivity to immune checkpoint blockade (e.g., anti-PD-1 treatment) following RPL15 inhibition

Ribosomal subunit biogenesis analysis:

• Nuclear extract preparation and analysis of pre-60S ribosomal particles

• Assessment of RPL15-RPL4 interactions through co-immunoprecipitation studies

These methodologies provide comprehensive tools for investigating how RPL15 inhibition impacts ribosomal stress responses and their downstream effects on cellular function and immune modulation.

What are the current limitations in RPL15 antibody-based research and potential solutions?

Current research involving RPL15 antibodies faces several methodological challenges:

Specificity considerations:

• The discrepancy between calculated (24 kDa) and observed (27 kDa) molecular weights of RPL15 necessitates careful antibody validation

• Multiple ribosomal proteins have similar molecular weights, requiring additional specificity controls

• Solution: Using known positive controls (HeLa cells, K-562 cells) and knockout/knockdown validation is recommended

Application limitations:

• While validated for WB, IHC, and IF/ICC, applications such as ChIP, flow cytometry, and in vivo imaging lack thorough validation

• Solution: Systematic validation across additional applications with appropriate positive and negative controls

Tissue-specific considerations:

• Current validation focuses primarily on specific cell lines and human colon tissue

• Solution: Expanded validation across diverse tissue types and pathological states will enhance research applicability

Technical challenges:

• Variability in antigen retrieval efficacy across different tissue fixation methods

• Solution: Protocol optimization for specific tissue preparation methods and fixation conditions

Addressing these limitations will advance the reliability and versatility of RPL15 antibody-based research applications across diverse experimental systems.

What are promising research directions for RPL15 in cancer immunotherapy?

Several promising research directions are emerging for RPL15 in cancer immunotherapy:

Development of RPL15-specific inhibitors:

• Current evidence suggests that RPL15-specific inhibitors might enhance antitumor immunity while potentially having lower cytotoxicity than dual-target compounds like TPT

• Camptothecin derivatives lacking TOP1 inhibitory activity could be explored as RPL15-specific inhibitors

Combination therapy approaches:

• Further investigation of RPL15 inhibition combined with immune checkpoint blockade (PD-1, CTLA-4) is warranted, as preliminary data shows increased CTL/Treg ratios and enhanced sensitivity to anti-PD-1 treatment

• Studies could explore synergy with other immunotherapy modalities beyond checkpoint inhibition

Biomarker development:

• Given the elevated expression of RPL15 in certain cancers (56.5% of colon cancers) , research into RPL15 as a predictive biomarker for immunotherapy response could be valuable

• Correlation studies between RPL15 expression levels and response to various immunotherapies across cancer types

Mechanistic elucidation:

• Further research into the precise mechanisms by which ribosomal stress induces DAMP secretion could uncover additional therapeutic targets

• Investigation of RPL15's role in regulating the tumor microenvironment beyond DAMP secretion and T cell populations

These research directions could significantly advance our understanding of RPL15's role in cancer biology and potentially lead to novel therapeutic strategies leveraging its immunomodulatory effects.